Therapeutic Agents for Neurodegenerative Disorders
A special issue of Molecules (ISSN 1420-3049). This special issue belongs to the section "Medicinal Chemistry".
Deadline for manuscript submissions: closed (31 May 2021) | Viewed by 7252
Special Issue Editors
Interests: neurotrasmitters; estrogens; neurotrophins; neurodegenerative disorders; drug discovery and development
Special Issues, Collections and Topics in MDPI journals
Interests: Dr. Ryan's interest is in how memories are formed and stored in the brain at the molecular level and how this may be altered in Alzheimer's disease
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
This Special Issue of Molecules provides a forum for the dissemination of the most recent findings on therapeutic agents for neurodegenerative diseases.
Neurodegenerative diseases such as Alzheimer’s, Parkinson’s, and Huntington’s diseases as well as amyotrophic lateral sclerosis pose extraordinary challenges for drug development. There is a great need for therapies to prevent and/or slow the progression of these disorders. The etiology of most neurodegenerative diseases is still unknown, but several factors are thought to contribute to the neurodegenerative process, such as oxidative stress, excitotoxicity, protein aggregation, vascular dysfunction, and neuroinflammation. These processes culminate in the death of specific neuronal populations, leading to cognitive and/or motor impairments, and they offer many potential therapeutic targets. Most current treatments for these disorders target single aspects of disease pathology. However, this strategy has yet to fulfil expectations in clinical trials, and focus has now turned towards therapeutics which target multiple aspects underlying neurodegeneration to ensure future treatment success. A number of these therapeutic targets also serve multiple roles as biomarkers and as theranostics. Drug designs have also shifted from treating neurodegenerative diseases at later stages of disease progression to focusing on preventive strategies at early stages of disease development.
We welcome the submission of research and review articles on the advances in every aspect of drug discovery in the field of neurodegenerative diseases.
Dr. Andrea Kwakowsky
Dr. Margaret Ryan
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Molecules is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- beta amyloid
- tau
- alpha-synuclein
- huntingtin
- autophagy
- neuromodulators
- neurotrophins
- natural compounds
- neuroinflammation
- vascular dysfunction
- neuronal death
- drug development
- therapeutic biomarkers
- blood–brain barrier
- small-molecule therapeutics
- theranostics
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.
Related Special Issue
- Therapeutic Agents for Neurodegenerative Disorders in Molecules (8 articles)
